Pharmaceutical Industry discussion, review, analysis, news and information.

An additional indication for CSL Behring (5950871)’s Rhophylac® Rh0(D) (Immune Globulin Intravenous [Human]) has just been granted marketing approval by the USFDA: treatment of immune thrombocytopenic purpura (ITP).

Administered intravenously, Rhophylac is indicated to raise platelet counts in Rh0(D)-positive, non-splenectomized adult patients with chronic ITP.

Having established efficacy and safety in over 10 years of use for other indications, Rhophylac offers high value pricing to help healthcare practitioners manage costs.

Characterized by a low number of platelets (<30 x 10(9)/L), immune thrombocytopenic purpura (ITP) is an autoimmune disease in which the immune system attacks and destroys the body's own platelets – the cells that prevent bleeding in blood vessels and facilitate clotting.

Read the full press release.